Fluoroquinolone antibiotics have potent activity against a broad spectrum of pathogenic bacteria and are safe and effective for many community-and hospitalacquired infections [1] . Ciprofloxacin, in particular, is effective for treatment of serious nosocomial infections, including those caused by Pseudomonas aeruginosa [1, 2] . Newer fluoroquinolones, including levofloxacin, gatifloxacin, and moxifloxacin, have improved activity against Streptococcus pneumoniae, including strains that
are resistant to penicillin, and use of these fluoroquinolones has increased substantially in the community for treatment of respiratory tract infections [3] [4] [5] .
Epidemiologic investigations and case reports link community fluoroquinolone use to fluoroquinoloneresistant S. pneumoniae [6] [7] [8] . In US hospitals, there is also an association between community sales of fluoroquinolones and the prevalence of ciprofloxacinresistant P. aeruginosa in intensive care units [9] . Furthermore, retrospective studies in multiple-hospital networks have found a positive association between increasing use of fluoroquinolones and fluoroquinoloneresistant P. aeruginosa [10, 11] . The Centers for Disease Control and Prevention (CDC) reports that the increase in hospital rates of fluoroquinolone-resistant P. aeruginosa is second only to the rate for methicillin-resistant Staphylococcus aureus [12] . This is especially worrisome, because fluoroquinolone resistance in P. aeruginosa is linked to resistance for unrelated antibiotics [9, 13, 14] .
Unfortunately, there are few new drugs in development for the treatment of resistant gram-negative bacterial infection [15] .
Antimicrobial resistance in a hospital is believed to reflect the impact of 3 variables: hospital antimicrobial use, crosstransmission of resistant strains, and introduction of antimicrobial-resistant organisms from the community [16] . However, these relationships have been difficult to quantify, in part because antimicrobial use data in the community and in hospitals are not readily available. We measured fluoroquinolone use in a network of US hospitals during a 3-year period (1999) (2000) (2001) . We also measured fluoroquinolone use in the communities surrounding these hospitals for 2 years, from March 1999 through February 2001. The purpose of this study was to determine whether both sites of use were independently and significantly associated with hospital rates of fluoroquinoloneresistant P. aeruginosa.
METHODS

Hospital antibiotic use in the Surveillance and Control of Pathogens of Epidemiologic Importance (SCOPE)-MediMedia Information Technology (MMIT) Antimicrobial Monitoring
Network. SCOPE is a nosocomial bacteremia surveillance network involving ∼40 medical-surgical hospitals throughout the United States [17] . SCOPE is coordinated at Virginia Commonwealth University in Richmond, Virginia. MMIT (Yardley, PA; http://www.mminfotech.com) performs detailed patientlevel analyses of drug use in ∼70 US nongovernment hospitals and links drug use to hospital and patient demographic data. The SCOPE-MMIT Antimicrobial Surveillance Network is an alliance between SCOPE and MMIT, and the network has measured inpatient antibiotic use, beginning with 19 MMIT hospitals in 1999 and expanding to 45 hospitals in 2004. All inpatient antibiotic dispensing data are electronically extracted from billing records. Drug identity is determined from recognition of codes from the Uniform System of Classification (IMS). Antibiotic use is identified by recognition of antibacterial drugs (code 15000), antiviral drugs (code 82000), and antifungal drugs (code 38000). For this report, patient-level data were aggregated for "hospital wide" antimicrobial use. The total number of grams of individual antibiotics and total patient-days (PD) are used to calculate the defined daily dose (DDD)/1000 PD [18, 19] . The DDDs for ciprofloxacin, levofloxacin, gatifloxacin, and moxifloxacin used in this study were 1000 mg, 500 mg, 400 mg, and 400 mg, respectively.
The database is validated at each new hospital from random patient profiles that detail all demographic characteristics, diagnoses, procedures, and drugs used by the patient. These sample profiles are sent to each hospital to confirm that all recorded information for individual patients has been received by MediMedia and interpreted accurately.
This study received an expedited review and was approved by the Institutional Review Board of Virginia Commonwealth University. Hospital demographic data. Demographic data for the year 2000 were obtained from the MediMedia database, the American Hospital Directory [20] , and Hospital Select [21] The density of community fluoroquinolone use surrounding each hospital was estimated using Zipfind.net (Bridger Systems). All zip codes within a 5-mile (∼8-km) and 10-mile (∼16-km) radius of the zip code of each SCOPE-MediMedia hospital were identified. The mean number of tablets per prescription, number of prescriptions, and tablet strength were used to estimate total number of grams dispensed. The population in each zip code was determined from data from the 2000 Census and used to calculate the number of DDDs per 1000 inhabitantdays for each antibiotic, as recommended by the World Health Organization (http://www.whocc.no/atcddd/).
Measurements of fluoroquinolone susceptibility for P. aeruginosa. Antibiograms for 1999-2001 were requested from all hospitals. We requested the methodology used to determine antimicrobial susceptibility, as well as policy toward duplicate isolates and surveillance cultures in the construction of the annual antibiogram. Antibiograms were constructed using NCCLS guidelines for the Kirby-Bauer disk diffusion method or by Vitek (bioMérieux) or MicroScan (Dade Behring) automated susceptibility testing. For hospitals that reported susceptibilities by unit or infection site (e.g., blood), data were aggregated so that rates of resistance included all clinical sources. Most hospitals reported fluoroquinolone susceptibility for P. aeruginosa using ciprofloxacin. Levofloxacin susceptibility was reported by 2 hospitals during 1999, by 4 hospitals during 2000, and by 3 hospitals during 2001.
Statistical analysis. Repeated-measures analysis of vari- ance assessed the significance of changes in antibiotic use and changes in fluoroquinolone susceptibility in hospitals for which data were available from 1999-2001. Least-squares linear regression was used to examine the univariate relationship between fluoroquinolone use in hospitals and in communities, as well as selected hospital demographic data, to rates of fluoroquinolone-resistant P. aeruginosa. We then used multiple linear regression to assess the significance of combined hospital and community fluoroquinolone use and the rates of fluoroquinolone-resistant P. aeruginosa during 1999 and 2000. The program JMP IN, version 4.0.4 (SAS Institute), was used for all analyses. A P value of !.05 was considered to be statistically significant. All tests were 2-tailed.
RESULTS
Hospital demographic data. All hospitals were general medical-surgical institutions, except for 1 women and children's hospital (table 1) . Data from this hospital are not included in the statistical analysis but do appear in the figures to contrast fluoroquinolone use and rates of resistance. There were no significant associations between hospital demographic data and rates of fluoroquinolone-resistant P. aeruginosa.
Hospital fluoroquinolone use. The mean hospital fluoroquinolone use across all hospitals, by quarter, is seen in figure  1 . The mean total amount of fluoroquinolone use (‫ע‬SD) during 1999 was DDD/1000 PD (24 hospitals ), but the decrease in ciprofloxacin use P p .0006 was not ( ). As a percentage of total fluoroquinolone P p .14 use, the rate of levofloxacin use increased from 64% in 1999 to 82% in 2001; ciprofloxacin use decreased from 28% to 17% during the same period.
Community fluoroquinolone use. The mean rate of community fluoroquinolone use surrounding all 35 hospitals, by quarter, is seen in figure 2 For 1999-2001, the women and children's hospital had the lowest rate of fluoroquinolone use and a low rate of fluoroquinolone-resistant P. aeruginosa ( figure 3 ). In contrast, the rate of community fluoroquinolone use surrounding this hospital was average ( figure 4) ), but community usage of ciprofloxacin was not statis-.0006 tically significant ( ). Hospital use of levofloxacin and P p .37 ciprofloxacin was not predictive of resistance in 1999. In the year 2000, the model explained one-half of the variation in rates of resistance ( ; ; ), and levoflox-2 R p .50 P p .003 n p 27 acin use both in the community ( ) and in the hospital P p .031 ( ) contributed significantly to the model. Ciproflox-P p .029 acin use was not predictive of rates of resistance in the community ( ) or in the hospital ( ). P p .83 P p .75
DISCUSSION
Resistance of P. aeruginosa to fluoroquinolones is mediated by multiple mechanisms, and the organism is often multidrug resistant [13] . Such strains cause endemic infections and are only susceptible to colistin (colistimethate sodium) [13, 24] . These strains have evolved when there are few drugs under development that are active against multidrug-resistant gramnegative bacteria [13, 15] . The mean rates of fluoroquinolone-resistant P. aeruginosa in our hospital network (29% in 1999, increasing to 38% in 2001) are similar to those in other reports. Surveillance from 250 US hospitals in the year 2000 found that 29% of P. aeruginosa were fluoroquinolone resistant [14] , a rate similar to that from the CDC Project ICARE hospitals (∼24% in 1998/1999) [12] . These reports of the mean rates of resistance, however, underemphasize marked variability between hospitals, from 16% to 60% during 2001 in our network. The women and children's hospital consistently had the lowest rates of resistance, from 11% in 1999 to 13% in 2001, as well as the lowest rates of fluoroquinolone use. This is the first report that antibiotic use in the hospital and surrounding communities explains much of this variability-something that has not been possible in previous studies that lack local antibiotic use data [9] [10] [11] [25] [26] [27] .
Fluoroquinolone use is a significant risk factor for selection of resistant P. aeruginosa in individual patients and in populations [9] [10] [11] [27] [28] [29] . Richard et al. [28] found that prior receipt of a fluoroquinolone was the main risk factor for infection with a quinolone-resistant gram-negative bacterium. They also reported that, of 206 hospitalized patients, the gastrointestinal tracts of 63 were colonized with fluoroquinolone-resistant bacteria [29] . One-half of these organisms were P. aeruginosa, and receipt of a fluoroquinolone within the preceding month, either in the hospital or in the community, was the main risk factor.
The observation that community antimicrobial use may contribute to antimicrobial resistance in hospitals is a relatively new phenomenon. Before the availability of fluoroquinolones, the antibiotics used most often in the community were not used in hospitals to treat serious infections. The exception has involved patients admitted from a long-term care facility at which use of potent antimicrobial agents is common [30] . In 1999, Fridkin et al. [31] reported from the National Nosocomial Surveillance System that fluoroquinolone resistance in P. aeruginosa was higher in community isolates than in hospital isolates. They speculated that this may be related to community use of fluoroquinolones. A report that the increase in fluoroquinolone-resistant P. aeruginosa in intensive care units in the United States is correlated with community fluoroquinolone use is consistent with our observations [9] . However, the relative rate of use of fluoroquinolones in the community (∼3 DDD/1000 inhabitant-days) is considerably lower than that in the hospital (∼150 DDD/1000 PD), strongly suggesting that hospital use is more likely to contribute to fluoroquinolone resistance in the hospital than is community use.
The finding that fluoroquinolone resistance is most closely linked to levofloxacin use (and not to ciprofloxacin use) is intriguing. Rates of fluoroquinolone resistance in P. aeruginosa were increasing before levofloxacin was widely used, so use of this agent cannot be solely responsible. However, levofloxacin may be more likely to select for resistant strains of P. aeruginosa than is ciprofloxacin. Peterson et al. [32] reported that the monthly prevalence of ciprofloxacin-resistant P. aeruginosa at Northwestern Memorial Hospital (Chicago, IL) increased from ∼7% in June 1992 to 25% by October 1995. This was more closely linked to ofloxacin use than to ciprofloxacin use. Bhavnani et al. [11] found that hospital expenditures for levofloxacin were associated with fluoroquinolone resistance in P. aeruginosa, whereas ciprofloxacin expenditures were not. When levofloxacin was approved for use in the United States in 1996, ciprofloxacin was more active against P. aeruginosa [1] , but recent surveillance reports indicate that susceptibility is now essentially identical [14] . There are, however, subtle differences between these 2 drugs that may explain these observations. Fluoroquinolone-resistant P. aeruginosa are most likely to originate in the gastrointestinal tract [29] . The bioavailability of levofloxacin is nearly 100%, whereas the bioavailability of ciprofloxacin is 60%-70% [1] . The higher gastrointestinal concentrations of ciprofloxacin may eliminate borderline fluoroquinolonesusceptible organisms, whereas lower gastrointestinal concentrations of levofloxacin may select for fluoroquinolone-resistant strains. Furthermore, in vitro serial passage studies by Gilbert et al. [33] report that levofloxacin is consistently more likely than ciprofloxacin to select for fluoroquinolone-resistant strains of P. aeruginosa.
There are limitations to our observations. First, hospitals did not use uniform methods to construct and report antibiograms.
Failure to eliminate duplicate isolates, for example, tends to increase the rate of reported resistance [34] . Second, there is potential for information bias, selection bias, and confounding during investigations that link aggregate antibiotic use to resistance [35] . Although we found no relationship of selected hospital demographic data to rates of resistance, there are other variables that may contribute to resistance in P. aeruginosa. In particular, patient-to-patient transmission is a frequent confounder of the relationship between drug use and resistance [12, 35, 36] . This, however, appears to be an unlikely explanation of our observations, because patient-to-patient transmission of drug-resistant P. aeruginosa is uncommon and is less important than drug exposure [37] . Finally, associations cannot by themselves prove causal relationships. However, the association between community fluoroquinolone use and hospital rates of resistance has now been replicated: the variability in rates of resistance correlated with use, antibiotic use preceded increasing resistance, and the results are biologically plausible.
Whether a return to more modest use of fluoroquinolones or preferential use of fluoroquinolones with a lower propensity to select for resistant strains will delay or reverse the rates of increasing resistance remains unclear. What is clear is that we are rapidly losing a valuable class of antibiotics for the treatment of serious nosocomial infections.
